Bicyclic Ligand-Biased Agonists of S1P1: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety Profiles-Reference-Cited by-同舟云学术

Bicyclic Ligand-Biased Agonists of S1P1: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety Profiles

Published:2021-01-25 Issue:3 Volume:64 Page:1454-1480
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Gilmore John L.¹^ORCID,Xiao Hai-Yun¹,Dhar T. G. Murali¹^ORCID,Yang Michael¹^ORCID,Xiao Zili¹,Yang Xiaoxia¹,Taylor Tracy L.¹,McIntyre Kim W.¹,Warrack Bethanne M.¹,Shi Hong¹,Levesque Paul C.¹,Marino Anthony M.¹,Cornelius Georgia¹,Mathur Arvind¹,Shen Ding Ren¹,Pang Jian¹,Cvijic Mary Ellen¹,Lehman-McKeeman Lois D.¹,Sun Huadong¹,Xie Jenny¹,Salter-Cid Luisa¹,Carter Percy H.¹,Dyckman Alaric J.¹^ORCID

Affiliation:

1. Bristol Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01109

Reference35 articles.

1. Phosphorylation of the Immunomodulatory Drug FTY720 by Sphingosine Kinases

2. Novel Immunomodulator FTY720 Is Phosphorylated in Rats and Humans To Form a Single Stereoisomer. Identification, Chemical Proof, and Biological Characterization of the Biologically Active Species and Its Enantiomer

3. Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis